Cheapest Foundayo UK: how to actually find the best price
Not a list of tricks. A method: what to compare, what the hidden costs are, where the traps sit, and how to make sure the cheapest option is also a safe one.
UK pharmacies have not yet published Foundayo pricing following the MHRA approval on 10 August 2026. When verified prices exist, the cheapest verified option by dose appears here, and in full on our discount and retail lists.
Discount price listLast reviewed: 23 August 2026
Compare the total, not the headline
The single most expensive mistake is comparing advertised medicine prices. What you actually pay is medicine plus consultation or prescription fee plus delivery, and providers distribute those costs differently on purpose. A provider with the cheapest medicine and a £39 consultation loses to one with a dearer tablet and no fee. Our tables compare the checkout total for exactly this reason, and the method is published in how we check prices.
Price the dose you will settle at
Foundayo escalates through six strengths, from 0.8 mg to 17.2 mg, with at least a month at each.1 With existing GLP-1 medicines, higher doses generally cost more, so the cheap starter month tells you little about your annual cost. Work out the likely price at 9 mg or 17.2 mg before committing to a provider, because that is the number you will live with. Our retail list is built dose by dose, and the dose steps guide explains where most people land.
The seven hidden costs
- Consultation or prescription fees, sometimes only revealed at the final step.
- Delivery, especially next-day or tracked options, and free-delivery thresholds that require overspending.
- The second-month price after an introductory offer expires.
- Subscription lock-ins, where the cheap rate depends on committing to several months.
- Cancellation terms, if the medicine does not suit you and you have prepaid.
- Bundled programmes, coaching or apps folded into the price whether you want them or not.
- Dose changes mid-plan, where escalating costs more than the plan you bought.
Timing the market
New medicines follow a predictable pricing arc. Launch prices are usually high while supply is limited, competition then pushes them down, and promotional pricing appears as providers fight for early customers. Foundayo is days old in the UK, so expect volatility for months rather than a settled price.2 Practical implication: avoid long prepaid commitments early, re-check prices when you reorder, and treat the last-checked date on every row as part of the information.
Cheapest is worthless if the pharmacy is not real
The rule that overrides price
A new medicine plus the search term "cheapest" is exactly where fake pharmacies fish. Anyone selling Foundayo without a prescription, at a fraction of the market rate, or before proper UK supply exists, is not selling you Foundayo. Verify the dispensing pharmacy on the GPhC register before paying anyone.3 Our red flags guide takes two minutes and is the best-value thing on this page.
Every provider in our tables has already been through manual checks, including certificate verification, before a price is published. That is what Dayo Verified means, and it is why our cheapest row is not simply the cheapest thing on the internet.
Ways to genuinely reduce the cost
- Check whether a lower dose maintains your result. Once you are stable, the lowest effective dose is both clinically sensible and cheaper. See maintenance.
- Compare again at each reorder. Loyalty is rarely rewarded in this market; switching provider is straightforward and covered in our switching pharmacy guide.
- Use verified codes only, tested at checkout: our discount codes page.
- Consider whether another medicine fits better on price and effect. Live comparisons for Mounjaro, the Wegovy injection and the Wegovy tablet are on Monj, iGovy and Ogovy.
- Do not forget the NHS route. Foundayo is not NHS funded while NICE evaluates it, but free NHS weight management support exists and costs nothing alongside any decision you make.4
Sources and references
- MHRA: UK first in Europe to authorise orforglipron for weight management and type 2 diabetes — authorisation date, indications and dose schedule
- BMJ 2026;394:e100547 — UK approval coverage and market context
- General Pharmaceutical Council register of pharmacies — verifying a UK dispensing pharmacy
- NICE — NHS evaluation process for new treatments
Reviewed against primary sources. See our editorial policy for how we source and update content.